Clinical and demographic characteristics
| Parameters | Transplanted n=15 | Non-transplanted n=45 | P value |
| Gender male (%) | 10 (66.7) | 40 (88.9) | 0.08 |
| Age (mean+SD) | 60.8+7.9 | 67.7+8.2 | 0.006 |
| Pack years (median+IQR) | 20 (0–36) | 35 (20–60) | 0.035 |
| Interval in years (median+IQR) | 10 (4–13) | 3 (0–5) | <0.001 |
| Lobe involved (n (%)) | |||
| Upper | 6 (40.0) | 16 (35.5) | 0.66 |
| Lower | 8 (53.3) | 28 (62.2) | |
| Location of tumour (n (%)) | |||
| Peripheral | 10 (66.7) | 33 (73.3) | 0.42 |
| Central | 5 (33.3) | 12 (26.7) | |
| Histology (n (%)) | |||
| Squamous | 6 (40.0) | 19 (42.2) | 0.90 |
| Adeno | 4 (26.7) | 17 (37.8) | 0.46 |
| Small cell | 2 (13.3) | 4 (8.9) | 0.46 |
| Large cell | 0 | 1 (2.2) | 0.70 |
| Stage (n (%)) | |||
| I | 1 (6.7) | 4 (8.9) | 0.60 |
| II | 2 (13.3) | 8 (17.8) | 0.53 |
| III | 1 (6.7) | 10 (22.2) | 0.17 |
| IV | 9 (66.7) | 20 (44.4) | 0.26 |
| Lung cancer treatment given (n (%)) | 10 (66.7) | 34 (75.6) | 0.18 |
| Median survival in month (95% CI) | 4 (0 to 10.3) | 11 (4 to 17.9) | 0.18 |
| 1-year survival – patients (%) | 27 | 43 | 0.26 |